Docetaxel
- PDF / 170,540 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 70 Downloads / 164 Views
1 S
Febrile neutropenia, thrombocytopenia and decreased neutrophils: case report A 63-year-old man developed febrile neutropenia, thrombocytopenia and decreased neutrophil during treatment with docetaxel for castration-resistant prostate cancer. The man presented with left-homonymous hemianopia in December 2015 (at the age of 64 years). Upon anamnesis, it was revealed that, he was diagnosed with prostate adenocarcinoma (cT3bN0M1b) in June 2012, subsequently started receiving bicalutamide and gonadotropin releasing hormone [luteinising hormone releasing hormone]. However, the prostate specific antigen (PSA) level was found to be increased. Therefore, unspecified anti-androgen replacement therapy was given, but no effect was observed. In September 2014 (at an approximate age of 63 years), he was diagnosed with castration-resistant prostate cancer. Previous therapy was therefore discontinued, and docetaxel was initiated [dosage and route not stated]. He subsequently developed grade 4 decrease in neutrophil count. The man’s docetaxel was therefore stopped after five courses, and cabazitaxel was initiated. Following the cabazitaxel therapy, disappearance of the bone metastasis was observed, however, multiple lung metastases appeared. The man’s therapy with docetaxel was thus re-initiated in September 2015 with other concomitant medications. The lung lesions showed a complete response eventually. However, he developed febrile neutropenia and thrombocytopenia, which were considered to be side-effects of docetaxel [durations of treatments to reactions onsets not stated]. Hence, docetaxel was discontinued. He further received enzalutamide in November 2015. Subsequently, the PSA levels decreased. In December 2015 at the age of 64 years, he presented with left-homonymous hemianopia (the current presentation). He also showed staggered walking. Upon further investigation, a diagnosis of T-cell rich type B-cell lymphoma (primary neurogenic lymphoma) was made [aetiology not stated]. Irradiation therapy was performed therefore and reduction in size of the brain tumour was noted. The neurological symptoms did not improve; however, no clear clinical deterioration was noted up-to three years after the radiation therapy [outcomes of the reactions not stated]. Yumiba S, et al. [A Case of Primary Central Nervous System Lymphoma that Developed during the Treatment of Castration-Resistant Prostate Cancer]. [Japanese]. Hinyokika 803505007 Kiyo 66: 49-52, No. 2, 29 Feb 2020. Available from: URL: http://doi.org/10.14989/ActaUrolJap_66_2_49 [Japanese; summarised from a translation]
0114-9954/20/1824-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 3 Oct 2020 No. 1824
Data Loading...
